Impact of Allopurinol on early and one-year outcomes of patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized controlled trial-Reference-Cited by-同舟云学术

Impact of Allopurinol on early and one-year outcomes of patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized controlled trial

Published:2023-01-23 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Daviran Nilgoon¹,Nateghian Hooman²,Separham Ahmad¹,Ghaffari Samad¹,Sohrabi Bahram¹,Aslanabadi Naser¹,Raadi Mehrdad¹,Asbagh Amirhosein Ghafouri²

Affiliation:

1. Cardiovascular research center, Tabriz University of Medical sciences, Tabriz, Iran

2. Research Center for Evidence‑Based Medicine, Iranian EBM Centre: A Joanna Briggs Institute Affiliated Group, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Abstract Purpose: Due to the potential benefits of allopurinol in ischemic reperfusion injury, this randomized control trial was performed to evaluate the pretreatment allopurinol effect on major adverse cardiovascular events (MACE) in patients undergoing primary percutaneous coronary intervention (pPCI). Methods: A randomized controlled trial was performed on 170 first-time STEMI patients undergoing pPCI. Before the pPCI, patients in intervention group (n=85) received 300 mg dose of allopurinol and control group (n=85) received placebo. Then, for the next 28 days, 100 mg of allopurinol was given to allopurinol group and placebo to the other group. Patients were compared regarding the baseline characteristics, clinical findings and one-year MACE. Results: Our findings showed that patients receiving allopurinol had significantly longer door-to-balloon time than the control group (60.76 ± 19.38 vs. 50.06 ± 16.38 P-value: 0.001). During one year of follow-up, HF, CVA and mortality occurred more frequently in allopurinol group but differences were not statistically significant. No significant difference was also seen between the two groups regarding MACE during follow-up or hospitalization (p-value: 0.179, 0.330 respectively). Kaplan-Meier curve could not show a significant difference between the two groups in terms of mortality and MACE (P-value: 0.317 and 0.128 respectively). Conclusion: According to findings of this trial allopurinol had no cardioprotective effect against adverse cardiovascular events or death in patients undergoing pPCI.

Publisher

Research Square Platform LLC

Reference39 articles.

1. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol [Internet]. 2019 Oct 1 [cited 2022 Dec 4];234(10):16812–23. Available from: https://pubmed.ncbi.nlm.nih.gov/30790284/

2. Chadwick Jayaraj J, Davatyan K, Subramanian SS, Priya J. Epidemiology of Myocardial Infarction. In: Myocardial Infarction. IntechOpen; 2019.

3. Fröhlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J [Internet]. 2013 Jun 14 [cited 2022 Dec 4];34(23):1714–24. Available from: https://pubmed.ncbi.nlm.nih.gov/23536610/

4. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest [Internet]. 2013 Jan 2 [cited 2022 Dec 4];123(1):92–100. Available from: https://pubmed.ncbi.nlm.nih.gov/23281415/

5. Ju C, Lai RWC, Li KHC, Hung JKF, Lai JCL, Ho J, et al. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. Rheumatology (United Kingdom). 2020 Sep 1;59(9):2340–9.